ISO 10993-1 Certification Agencies Compared to SN EN ISO 10993-17:2023
Why compare SN EN ISO 10993-17:2023 and ISO 10993-1 certification agencies
This comparison is essential for professionals in the healthcare technology sector who are navigating the complex landscape of regulatory compliance and risk assessment for medical devices. Regulatory bodies, manufacturers, and quality assurance teams are often tasked with ensuring compliance with ISO 10993 standards. Understanding the nuances between SN EN ISO 10993-17:2023 and the requirements set forth by ISO 10993-1 certification agencies will help stakeholders make informed decisions about which standard to pursue based on their specific needs, particularly concerning toxicological risk assessments and biocompatibility evaluations.
How SN EN ISO 10993-17:2023 approaches the topic
SN EN ISO 10993-17:2023 focuses on the toxicological risk assessment of constituents in medical devices as part of the biological evaluation process. This standard outlines procedures for evaluating the potential hazards associated with chemical constituents, including their toxicological profiles and exposure levels. It emphasizes the importance of chemical characterization information and risk evaluation criteria, allowing for a structured approach to identifying hazardous constituents and calculating tolerable contact doses. The document also highlights risk assessment principles and provides guidance on identifying human carcinogens, ensuring that manufacturers have a robust framework to assess the safety of their products in alignment with international regulations such as EU Regulation 2017/745.
How ISO 10993-1 certification agencies approaches the topic
ISO 10993-1 serves as a foundational standard for the biological evaluation of medical devices, encompassing various aspects of biocompatibility and toxicological risk assessment. Certification agencies following ISO 10993-1 focus on a comprehensive evaluation of the biological safety of materials used in medical devices. The standard provides a framework for risk management, including hazard identification and risk estimation, but does not delve into the specific toxicological assessments detailed in SN EN ISO 10993-17:2023. Agencies assess compliance with ISO 10993-1 by reviewing documentation related to biological evaluations and ensuring adherence to the outlined procedures for assessing the potential biological risks posed by device constituents.
Side-by-side comparison
| Criteria | SN EN ISO 10993-17:2023 | ISO 10993-1 Certification Agencies |
|---|---|---|
| Scope | Focuses on toxicological risk assessment | Covers biological evaluation of devices |
| Audience | Manufacturers and regulatory bodies | Certification agencies and manufacturers |
| Cost/Effort | Requires detailed toxicological studies | Involves comprehensive documentation review |
| Certification Mechanism | Not a certification body, procedural guide | Certification based on compliance assessment |
| Typical Use Cases | Risk assessment for new materials/devices | General biocompatibility evaluation |
When to choose which
- If you need a detailed toxicological risk assessment for new materials in your medical device, choose SN EN ISO 10993-17:2023.
- If your focus is on achieving general compliance for biocompatibility assessment, opt for ISO 10993-1 certification.
- If you are preparing documentation for regulatory approval in the EU, consider both standards but prioritize SN EN ISO 10993-17:2023 for specific toxicological evaluations.
- If your organization is already compliant with ISO 13485 and you are assessing potential biological risks, leverage ISO 10993-1 certification to align with established quality management practices.